Article

Exploring Racial Differences in Pathological Complete Response to Neoadjuvant Chemotherapy and Pembrolizumab in Triple-Negative Breast Cancer

2025-06-27

Abstract excerpt

<title>Abstract</title> <p><underline>Background</underline> Triple-negative breast cancer (TNBC) is a high-risk subtype marked by aggressive behavior and limited treatment options. Neoadjuvant chemoimmunotherapy with pembrolizumab has improved pathologic complete response (pCR) rates in early-stage TNBC. However, racial disparities persist in TNBC outcomes, and data on how these disparities affect response to ch...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e1a4624f-8897-5b94-8bb4-563e2ec6feb5
DOI: 10.21203/rs.3.rs-6838801/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Exploring Racial Differences in Pathological Complete Response to Neoadjuvant Chemotherapy and Pembrolizumab in Triple-Negative Breast CancerDOI 10.21203/rs.3.rs-6838801/v1Read

BRCA1/2 Mutations and Efficacy of Pembrolizumab-Based Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Real-World Multicenter AnalysisSemantic proximity Read

Integrative spatial omics reveals distinct tumor-promoting multicellular niches and immunosuppressive mechanisms in Black American and White American patients with TNBCSemantic proximity Read

Racial disparities in breast cancer diagnosis and treatment by hormone receptor and HER2 status.Semantic proximity Read

Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer.Semantic proximity Read

Associations of Immune Checkpoint Predictive Biomarkers (MHC-I and MHC-II) with Clinical and Molecular Features in a Diverse Breast Cancer CohortSemantic proximity Read

Biologic, demographic, and social factors affecting triple negative breast cancer outcomes.Semantic proximity Read

Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry.Semantic proximity Read

Immunogenomic Profiling and Pathological Response Results From a Clinical Trial of Docetaxel and Carboplatin in Triple Negative Breast CancerSemantic proximity Read

Biomarker Guided Chemotherapy and Immunotherapy Response in Asian Triple-Negative Breast Cancer: A Systematic ReviewSemantic proximity Read

Population-specific patterns in assessing molecular subtypes of young black females with triple-negative breast cancerSemantic proximity Read

Differences in the mutational landscape of triple-negative breast cancer in African Americans and Caucasians.Semantic proximity Read

Pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer - one clinic experience.Semantic proximity Read